The Schnepp laboratory focuses on aggressive solid tumors including high-risk neuroblastoma, rhabdomyosarcoma and medulloblastoma. Adult tumors of these types tend to have more mutations that can in turn be targeted by therapies than their pediatric counterparts. This verifies the need to identify additional druggable targets in the pediatric forms of these tumors. Previous laboratory work has identified the RNA-binding proteins (RBP) LIN28B and Musashi 2 (MSI2) as drivers of neuroblastoma. This leads researchers to believe that RBPs may be involved in other cancers as well. Prior studies have identified several RBPs as crucial to tumor development in medulloblastoma cell lines. Based on this preliminary data, researchers hypothesize that RBPs may play critical roles in medulloblastoma development. This project aims to be a comprehensive investigation of the role of RBPs, with the eventual goal of nominating targets for the treatment of these tumors and others. Access to cell lines from the Children’s Brain Tumor Network allows researchers to assess RBP vulnerabilities in as many models as possible, increasing the efficiency and impact of this project.
What are the goals of this project?
This project aims to investigate the role of RNA binding proteins (RBPs) in the development of pediatric tumors including medulloblastoma.
What is the impact of this project?
Compared to their adult counterparts, pediatric cancers have fewer mutations that can be targeted for therapies, so the exploration of RBPs will open a new avenue of treatments for these tumors.
Why is the CBTN request important to this project?
The cell lines provided by the Children’s Brain Tumor network allow researchers a wide range of models for use in this project.
The Children's Brain Tumor Network will contribute to this project by providing cell lines.
Robert Schnepp, MD, PhD
Pediatric Oncology Research ProgramCell and Molecular Biology
Anna M. Kenney, PhD
Dr. Kenney's research focuses on cell cycle control in cerebellar development and medulloblastoma, a pediatric brain tumor that arises in the cerebellum. These tumors are the most common solid malignancy of childhood. Current treatments for medulloblastomas include surgical resection, chemotherapy,
Shubin Shahab, MD, PhD
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He is a
Children’s Hospital of Philadelphia
Michael Taylor, MD, PhD, FRCS(C)
Dr. Taylor’s laboratory plans to use the tools of forward and reverse genetics to better understand the underlying biology of medulloblastoma and ependymoma, two of the most common malignant paediatric brain tumours.In forward genetic approaches, the normal cells that are thought to give rise to a c
Tobey J. MacDonald, MD
Dr. MacDonald's research areas of interest include basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling basic and translational research of childhood brain tumors with a primar
Winship Cancer Institute
Children’s Hospital of PhiladelphiaJoined on
Operations Center for the Children’s Brain Tumor Tissue Consortium, the Children’s Hospital of Philadelphia (CHOP) is currently ranked 1st nationally for their Pediatric Cancer Program by U.S. News & World Report. CHOP’s Biobank is home to the CBTTC’s pediatric brain and CNS tumor biorepository; the
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature